Welcome to our dedicated page for Immunic SEC filings (Ticker: IMUX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Immunic, Inc. (IMUX) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission. As a Nasdaq-listed biotechnology issuer, Immunic uses filings such as Forms 10-K, 10-Q, and 8-K to report on its financial condition, clinical development progress, capital structure, and material corporate events.
Current reports on Form 8-K are particularly relevant for tracking Immunic’s milestones. Recent 8-K filings reference press releases on quarterly financial results and corporate updates, including spending on research and development for vidofludimus calcium (IMU-838) and other programs, as well as financings such as registered direct offerings and underwritten public offerings. Other 8-Ks describe presentation of new multiple sclerosis data at major scientific meetings and provide details on items like stock appreciation rights grants and Nasdaq listing notices regarding minimum bid price requirements.
Investors can also use SEC filings to monitor liquidity and risk disclosures, where Immunic discusses its cash and cash equivalents, the need to raise additional capital to fund operations, and the implications of financing structures. Filings may further elaborate on the company’s intellectual property strategy for vidofludimus calcium and other pipeline assets, complementing information in press releases.
On Stock Titan, these documents are supplemented with AI-powered summaries that explain key points in accessible language, helping readers quickly understand the significance of lengthy filings. Real-time updates from EDGAR ensure that new IMUX filings, including 10-Q and 10-K reports and any Form 4 insider transaction disclosures when available, are added promptly so users can review changes in ownership, compensation-related grants, and other governance matters alongside Immunic’s clinical and financial reporting.
Immunic, Inc. is registering up to 458,152,000 shares of common stock for resale by selling stockholders, consisting of up to 229,076,000 Pre-Funded Warrant Shares and up to 229,076,000 Common Warrant Shares. The company is not selling any shares and will receive proceeds only if Warrants are exercised for cash.
The Resale Shares equal approximately 67% of outstanding common stock on a pre-split basis. The company plans a stockholder vote on a reverse split (1-for-10 to 1-for-30) and intends to effect the Reverse Stock Split prior to the registration statement’s effectiveness. The private placement closed on February 17, 2026 and generated gross proceeds of $200.0M.
Immunic, Inc. announced that it has regained compliance with Nasdaq’s Minimum Bid Price Requirement for continued listing on The Nasdaq Capital Market. Nasdaq confirmed that the company’s common stock closed at or above $1.00 per share for 20 consecutive business days from February 27, 2026 to March 26, 2026, and the matter is now closed.
The company is a late-stage biotechnology business focused on novel oral therapies for neurologic diseases. Its lead candidate, vidofludimus calcium (IMU-838), is in phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, and is supported by earlier phase 2 results in multiple sclerosis and other conditions.
IMMUNIC, INC. has filed an initial Form 3 ownership report for director Jon Congleton. This filing identifies him as a board member but shows no reported transactions or derivative positions in the data provided. It is a routine regulatory disclosure about insider status.
Immunic, Inc. has appointed veteran biopharmaceutical executive Jon Congleton to its board of directors, effective March 27, 2026, as a Class II director with a term running until the 2028 annual meeting. He will also chair the board’s Compensation Committee, adding extensive CNS and multiple sclerosis commercialization experience to the company’s governance.
In connection with his appointment, Congleton received stock options to purchase 500,000 shares of common stock, vesting monthly over three years at an exercise price equal to the March 27, 2026 Nasdaq closing price, subject to shareholder approval of an increase in shares reserved under Immunic’s 2019 Omnibus Equity Incentive Plan. The board size increased from eight to nine directors. Immunic highlights Congleton’s nearly 40-year biopharma background and notes its lead MS asset, vidofludimus calcium, is in phase 3 trials with top-line data expected by the end of 2026.
Immunic, Inc. ownership disclosure: Deep Track Capital and affiliated entities report beneficial ownership of 11,454,000 shares of Common Stock, representing 8.69% of the class as of March 4, 2026.
The filing states this figure was determined using 131,738,724 shares, calculated from 120,284,724 shares outstanding as of November 11, 2025 and 11,454,000 shares issuable upon conversion of Pre-Funded Warrants and Warrants subject to a 9.99% exercise limitation. The reported holdings include Pre-Funded Warrants and Warrants split among Deep Track entities: 4,476,815 held by Deep Track Biotechnology Master Fund, Ltd. and 1,250,185 held by Deep Track Special Opportunities Fund, LP, each subject to the Maximum Percentage limitation.
Immunic, Inc. is asking stockholders to approve a reverse stock split of its common stock, at a ratio between 1-for-10 and 1-for-30, to be implemented at the board’s discretion within one year of approval. The main goal is to raise the per‑share trading price and help the company regain and maintain compliance with Nasdaq’s $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.
As of the February 20, 2026 record date, Immunic had 130,464,825 shares outstanding and is authorized to issue up to 500,000,000 shares. The reverse split would reduce the number of shares outstanding proportionally but leave percentage ownership and voting power generally unchanged, aside from cash paid in lieu of fractional shares.
The proxy explains that failure to approve the reverse split could increase the risk of Nasdaq delisting, which may hurt liquidity and access to capital. It also notes a February 2026 securities purchase agreement for pre‑funded and common warrants, which requires Immunic to obtain stockholder approval of this reverse split, with a breach risk if approval is not obtained.
IMMUNIC, INC. received an initial ownership report from a group of BVF-affiliated investment funds and Mark N. Lampert, jointly filing a Form 3 as reporting persons. They disclose holdings of common stock as well as multiple series of pre-funded warrants and common warrants tied to Immunic shares.
The reporting persons hold 2024, 2025 and 2026 pre-funded warrants that are immediately exercisable for an aggregate of 8,580,151, 13,335,000 and 53,257,500 shares of common stock, each at an exercise price of $0.0001 per share. These pre-funded warrants do not expire but cannot be exercised if such exercise would push their beneficial ownership above 9.9% or 9.99% of Immunic’s outstanding common stock, as specified for each series.
They also hold common warrants exercisable for an aggregate of 53,257,500 shares of common stock at an exercise price of $0.873220 per share following the issuer’s reverse stock split. These common warrants are exercisable until the earlier of 30 trading days after topline data from Immunic’s Phase 3 ENSURE trials, immediately upon certain exercises of the 2026 pre-funded warrants, or February 17, 2031, and are likewise subject to a 9.99% beneficial ownership cap. Each reporting person disclaims beneficial ownership beyond its pecuniary interest.
IMMUNIC, INC. director Robert Thorvald Nagel filed an initial ownership report on Form 3. This filing establishes his status as an insider of the company and provides the baseline record of his beneficial ownership in IMMUNIC’s securities as required by U.S. securities regulations. No transactions are reported.
Immunic, Inc. reports on its late-stage biotech portfolio and financing position for the year ended December 31, 2025. The company is advancing vidofludimus calcium through two global Phase 3 ENSURE trials in relapsing multiple sclerosis, with 1,121 and 1,100 patients enrolled and top-line data expected by the end of 2026. Phase 2 CALLIPER data in progressive multiple sclerosis and long-term EMPhASIS extension data in relapsing-remitting multiple sclerosis show reduced disability worsening and a favorable safety profile. IMU-856 has shown gut barrier and GLP-1 benefits in a Phase 1b celiac study, and IMU-381 remains in preclinical testing.
Immunic has incurred an accumulated deficit of approximately $608.6 million and held about $15.5 million in cash and cash equivalents as of December 31, 2025, after raising roughly $496.3 million since inception. A February 2026 private placement added approximately $187.0 million of net cash proceeds, which management believes funds operations beyond twelve months. The company also exchanged 51,087,000 Series B warrants for a 5% synthetic royalty on future vidofludimus calcium sales, faces Nasdaq minimum bid price compliance deadlines with a planned reverse stock split, and is initiating a CEO search while refreshing its board leadership.
Immunic, Inc. reported a 2025 net loss of $97.2M, slightly improved from $100.5M in 2024, as operating expenses rose modestly to $103.2M driven mainly by research and development spending of $82.0M.
The company highlighted an oversubscribed private placement of up to $400M in gross proceeds, including $200M already raised, which it expects to fund completion of phase 3 ENSURE trials in relapsing multiple sclerosis, initiate a phase 3 program in primary progressive multiple sclerosis and begin building a commercial organization. Management expects ENSURE top-line data by the end of 2026, a planned RMS NDA submission in the United States in mid-2027, and is targeting a potential regulatory approval date in 2028.